Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
Case Report
Case Report, GI/GU/Thoracic/Non Vascular Interventions
Case Report, Interventional Oncology
Case Report, Interventional Radiology
Case Report, Pediatric Interventional Radiology
Case Report, Vascular Interventions
Case Series
Case Series, Interventional Oncology
Case Series, Vascular Interventions
Editorial
GI/GU/Thoracic/Non-Vascular Interventions, Case Report
GI/GU/Thoracic/Non-vascular Interventions, Original Article
GI/GU/Thoracic/Non-Vascular Interventions, Original Research
GI/GU/Thoracic/Nonvascular Interventions, Case Report
Interventional Oncology, Case Report
Interventional Oncology, Original Research
Interventional Oncology, Patient Care, Practice Management and Education
Interventional Oncology, Technical Innovation
Interventions Oncology, Case Report
Interventions Oncology, Original Research
Letter to Editor
Letter to the Editor
Musculoskeletal Interventions, Case Report
Original Research
Original Research, GI/GU/Thoracic/Non-vascular Interventions
Original Research, GI/GU/Thoracic/Nonvascular Interventions
Original Research, Interventional Oncology
Original Research, Neurologic Interventions
Original Research, Vascular Interventions
PATIENT CARE, PRACTICE MANAGEMENT AND EDUCATION
Patient Care, Practice Management and Education, Original Research
Pediatric Interventional Radiology, Case Report
Pediatric Interventional Radiology, Original Article
Pediatric Interventional Radiology, Original Research
Research Article
Review Article
Review Article, Vascular Interventions
TECHNICAL INNOVATION
Technical Innovation, GI/GU/Thoracic/Nonvasculat Interventions
Technical Innovation, Interventional Oncology
Vascular Interventions, Case Report
Vascular Interventions, Original Research
Vascular Interventions, Technical Innovation
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
Case Report
Case Report, GI/GU/Thoracic/Non Vascular Interventions
Case Report, Interventional Oncology
Case Report, Interventional Radiology
Case Report, Pediatric Interventional Radiology
Case Report, Vascular Interventions
Case Series
Case Series, Interventional Oncology
Case Series, Vascular Interventions
Editorial
GI/GU/Thoracic/Non-Vascular Interventions, Case Report
GI/GU/Thoracic/Non-vascular Interventions, Original Article
GI/GU/Thoracic/Non-Vascular Interventions, Original Research
GI/GU/Thoracic/Nonvascular Interventions, Case Report
Interventional Oncology, Case Report
Interventional Oncology, Original Research
Interventional Oncology, Patient Care, Practice Management and Education
Interventional Oncology, Technical Innovation
Interventions Oncology, Case Report
Interventions Oncology, Original Research
Letter to Editor
Letter to the Editor
Musculoskeletal Interventions, Case Report
Original Research
Original Research, GI/GU/Thoracic/Non-vascular Interventions
Original Research, GI/GU/Thoracic/Nonvascular Interventions
Original Research, Interventional Oncology
Original Research, Neurologic Interventions
Original Research, Vascular Interventions
PATIENT CARE, PRACTICE MANAGEMENT AND EDUCATION
Patient Care, Practice Management and Education, Original Research
Pediatric Interventional Radiology, Case Report
Pediatric Interventional Radiology, Original Article
Pediatric Interventional Radiology, Original Research
Research Article
Review Article
Review Article, Vascular Interventions
TECHNICAL INNOVATION
Technical Innovation, GI/GU/Thoracic/Nonvasculat Interventions
Technical Innovation, Interventional Oncology
Vascular Interventions, Case Report
Vascular Interventions, Original Research
Vascular Interventions, Technical Innovation
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
Case Report
Case Report, GI/GU/Thoracic/Non Vascular Interventions
Case Report, Interventional Oncology
Case Report, Interventional Radiology
Case Report, Pediatric Interventional Radiology
Case Report, Vascular Interventions
Case Series
Case Series, Interventional Oncology
Case Series, Vascular Interventions
Editorial
GI/GU/Thoracic/Non-Vascular Interventions, Case Report
GI/GU/Thoracic/Non-vascular Interventions, Original Article
GI/GU/Thoracic/Non-Vascular Interventions, Original Research
GI/GU/Thoracic/Nonvascular Interventions, Case Report
Interventional Oncology, Case Report
Interventional Oncology, Original Research
Interventional Oncology, Patient Care, Practice Management and Education
Interventional Oncology, Technical Innovation
Interventions Oncology, Case Report
Interventions Oncology, Original Research
Letter to Editor
Letter to the Editor
Musculoskeletal Interventions, Case Report
Original Research
Original Research, GI/GU/Thoracic/Non-vascular Interventions
Original Research, GI/GU/Thoracic/Nonvascular Interventions
Original Research, Interventional Oncology
Original Research, Neurologic Interventions
Original Research, Vascular Interventions
PATIENT CARE, PRACTICE MANAGEMENT AND EDUCATION
Patient Care, Practice Management and Education, Original Research
Pediatric Interventional Radiology, Case Report
Pediatric Interventional Radiology, Original Article
Pediatric Interventional Radiology, Original Research
Research Article
Review Article
Review Article, Vascular Interventions
TECHNICAL INNOVATION
Technical Innovation, GI/GU/Thoracic/Nonvasculat Interventions
Technical Innovation, Interventional Oncology
Vascular Interventions, Case Report
Vascular Interventions, Original Research
Vascular Interventions, Technical Innovation
View/Download PDF

Translate this page into:

Interventional Oncology
Case Report
2023
:7;
12
doi:
10.25259/AJIR_17_2023

Treatment of hepatocellular carcinoma with arterioportal shunting using balloon-assisted transarterial yttrium-90 radiation segmentectomy: A case report

Department of Interventional Radiology, Georgetown School of Medicine, Washington, United States,
Department of Interventional Radiology, MedStar Washington Hospital Center, Washington, United States.

*Corresponding author: Gajan Sivananthan, Department of Interventional Radiology, MedStar Washington Hospital Center, Washington, United States. gajan.sivananthan@medstar.net

Licence
This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-Share Alike 4.0 License, which allows others to remix, transform, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

How to cite this article: Kolyvas P, Aljundi M, Sivananthan G. Treatment of hepatocellular carcinoma with arterioportal shunting using balloon-assisted transarterial yttrium-90 radiation segmentectomy: A case report. Am J Interv Radiol 2023;7:12.

Abstract

Portal vein tumor thrombus (PVTT) is a common finding associated with hepatocellular carcinoma (HCC) often further complicated by arterioportal shunting. While radioembolization with Yttrium-90 (Y-90) is the preferred treatment for HCC with PVTT, shunting can complicate particle delivery. Here, we describe a case of a 65-year-old man with HCC and significant shunting from the segment IV hepatic artery into the left and right portal veins due to a PVTT. We performed a balloon-assisted radiation segmentectomy by occluding the hepatic artery supplying the PVTT to minimize arterioportal shunting and promote redistribution of particles into the tumor bed. Post Y-90 bremsstrahlung scan correlated with appropriate uptake. One-month follow-up magnetic resonance imaging demonstrated response to treatment with decreased tumor thrombus in the left portal vein. Here, we demonstrate that balloon-occlusion-assisted transarterial radiation segmentectomy could be a beneficial approach for improving tumor response and reducing complications in individuals with HCC and arterioportal shunting.

Keywords

Balloon-occlusion microcatheter
Case report
Hepatocellular carcinoma
Portal vein tumor thrombus
Y-90 radioembolization

INTRODUCTION

Radioembolization with Yttrium-90 (Y-90) is the locoregional treatment of choice in patients with hepatocellular carcinoma (HCC) and portal vein tumor thrombus (PVTT). Radiation segmentectomy, defined as radioembolization of two or fewer segments of the liver, has been shown to improve outcomes in patients with PVTT when doses >205 Gy are utilized compared with those patients who receive lower doses.[1,2] Unfortunately, arterioportal venous shunts (APS), often seen concurrently with HCC PVTT, have been hypothesized to decrease the response to treatment and increase adverse events. This is thought to be a result of poor implantation of microparticles in the tumor as the particles exit through the capillary bed without stasis, reducing the therapeutic dose, and increasing the rate of adverse events by redistributing particles to non-target liver segments.[3] This shunting is often minor and limited to the tumor-involved segment or lobe. Rarely, a major shunt can result in shunting to both the involved and uninvolved lobes as well as the extrahepatic portal system. In these patients with major shunts, segmentectomy dosing cannot be delivered as the dose would be redistributed to the entire liver.[4] We describe a case where we used a balloon-occlusion microcatheter in the hepatic artery supplying PVTT to minimize arterioportal shunting and promote redistribution of particles into the tumor bed, specifically the PVTT component, during Y-90 glass microspheres radiation segmentectomy in a patient with HCC and APS. The Institutional Review Board approval was not required for this report.

CASE REPORT

A 65-year-old male with hepatitis C cirrhosis, chronic kidney disease, and recently diagnosed HCC presented with abdominal pain, decreased appetite, and weight loss. He was risk stratified as Child-Pugh 5A, albumin-bilirubin grade 1, and eastern cooperative oncology group grade 1 and referred for Y-90 treatment. Magnetic resonance imaging (MRI) demonstrated extensive bilobar HCC with enhancing tumor thrombus in the left portal vein as well as porta hepatis nodal metastasis [Figure 1]. At presentation, vital signs were within normal limits, total bilirubin level was 0.2 mg/dL, and alpha-fetoprotein was 9.6 ng/mL (normal range, <10 ng/mL). Given the extensive liver-centered malignancy burden with vascular invasion in the setting of preserved liver function and functional status, the decision was made to proceed with radioembolization with planned segmentectomy dose to the PVTT and lobar treatment to the left lobe.

A 65-year-old male with bilobar hepatocellular carcinoma and enhancing tumor thrombus in the left portal vein who presented with abdominal pain, decreased appetite, and weight loss. (a) Axial T1-weighted magnetic resonance imaging post contrast images in arterial phase showing multiple enhancing masses throughout the liver with arterially enhancing tumor thrombus in the left portal vein (black arrow) and (b) delayed phase with delayed washout (white arrow).
Figure 1:
A 65-year-old male with bilobar hepatocellular carcinoma and enhancing tumor thrombus in the left portal vein who presented with abdominal pain, decreased appetite, and weight loss. (a) Axial T1-weighted magnetic resonance imaging post contrast images in arterial phase showing multiple enhancing masses throughout the liver with arterially enhancing tumor thrombus in the left portal vein (black arrow) and (b) delayed phase with delayed washout (white arrow).

Digital subtraction angiogram (DSA) performed through a conventional microcatheter in the left hepatic artery demonstrated rapid shunting into the left and right portal veins. Similarly, a DSA with the sniper microcatheter (Embolix, Los Altos, California) with the balloon deflated and positioned in the segment IV branch of the left hepatic artery demonstrated subtle tumor blush in the left lobe with quick opacification of the right and left portal veins [Figure 2a]. Cone-beam computed tomography (CBCT) was performed with a rate of 1 mL/s for a total volume of 10 mL and demonstrated enhancement of the right and left hepatic lobe parenchyma [Figure 2b]. Repeat DSA and CBCT with balloon occlusion of the segment IV branch demonstrated improved tumor enhancement without arterioportal shunting into the right lobe [Figure 3a and b]. Tc-99 m macroaggregated albumin (MAA) was administered into segment IV during balloon occlusion and single-photon emission computed tomography–computed tomography demonstrated high activity in the left lobe tumor as well as the left portal vein thrombus with minimal uptake in the right hepatic lobe [Figure 4]. Pre-treatment Tc-99m MAA scintigram demonstrated a lung shunt of 10% and perfused volume of 790 mL. The left lobe of the liver, including the left PVTT, was treated with Y-90 glass microspheres (BTG International, Ottawa, Canada) utilizing balloon occlusion in the same fashion. The total activity delivered was 4.878 GBq, with a 286 Gy dose delivered to the perfused liver volume of 790 mL and a dose delivered to the lung of 24.39 Gy. Post Y-90 bremsstrahlung scan correlated with the mapping study [Figure 5]. There were no intraprocedural complications and 1-month follow-up MRI demonstrated response to treatment with decreased tumor thrombus in the left portal vein [Figure 6].

65-year-old male with bilobar hepatocellular carcinoma and enhancing tumor thrombus in the left portal vein who presented with abdominal pain, decreased appetite, and weight loss. (a) Digital subtraction angiography without balloon occlusion demonstrates minimal tumor blush and quick opacification of both left and right portal veins (black arrow). (b) Coronal contrast-enhanced cone beam computed tomography demonstrates opacification of the portal vein on arterial phase (white arrow) consistent with arterioportal shunting.
Figure 2:
65-year-old male with bilobar hepatocellular carcinoma and enhancing tumor thrombus in the left portal vein who presented with abdominal pain, decreased appetite, and weight loss. (a) Digital subtraction angiography without balloon occlusion demonstrates minimal tumor blush and quick opacification of both left and right portal veins (black arrow). (b) Coronal contrast-enhanced cone beam computed tomography demonstrates opacification of the portal vein on arterial phase (white arrow) consistent with arterioportal shunting.
A 65-year-old male with bilobar hepatocellular carcinoma and enhancing tumor thrombus in the left portal vein who presented with abdominal pain, decreased appetite, and weight loss. (a) Digital subtraction angiography through the Sniper balloon microcatheter with balloon occlusion showing improved tumor enhancement in segment IV, including tumor thrombus in the left portal vein (black arrow). (b) Coronal contrast enhanced cone beam computed tomography showing parenchymal enhancement in segment IV with much decreased arterioportal shunting.
Figure 3:
A 65-year-old male with bilobar hepatocellular carcinoma and enhancing tumor thrombus in the left portal vein who presented with abdominal pain, decreased appetite, and weight loss. (a) Digital subtraction angiography through the Sniper balloon microcatheter with balloon occlusion showing improved tumor enhancement in segment IV, including tumor thrombus in the left portal vein (black arrow). (b) Coronal contrast enhanced cone beam computed tomography showing parenchymal enhancement in segment IV with much decreased arterioportal shunting.
A 65-year-old male with bilobar hepatocellular carcinoma and enhancing tumor thrombus in the left portal vein who presented with abdominal pain, decreased appetite, and weight loss. Axial single-photon emission computed tomography-computed tomography image after 99m TC macroaggregated albumin (MAA) administration into segment IV artery demonstrating high activity within the targeted tumor in segment IV and left hepatic lobe with minimal accumulation of MAA in the right hepatic lobe.
Figure 4:
A 65-year-old male with bilobar hepatocellular carcinoma and enhancing tumor thrombus in the left portal vein who presented with abdominal pain, decreased appetite, and weight loss. Axial single-photon emission computed tomography-computed tomography image after 99m TC macroaggregated albumin (MAA) administration into segment IV artery demonstrating high activity within the targeted tumor in segment IV and left hepatic lobe with minimal accumulation of MAA in the right hepatic lobe.
A 65-year-old male with bilobar hepatocellular carcinoma and enhancing tumor thrombus in the left portal vein who presented with abdominal pain, decreased appetite, and weight loss. Bremsstrahlung scan obtained post Y-90 glass microsphere treatment using balloon occlusion technique showing maximum activity in segment IV and the left hepatic lobe (white arrow) with minimal uptake in the right hepatic lobe.
Figure 5:
A 65-year-old male with bilobar hepatocellular carcinoma and enhancing tumor thrombus in the left portal vein who presented with abdominal pain, decreased appetite, and weight loss. Bremsstrahlung scan obtained post Y-90 glass microsphere treatment using balloon occlusion technique showing maximum activity in segment IV and the left hepatic lobe (white arrow) with minimal uptake in the right hepatic lobe.
A 65-year-old male with bilobar hepatocellular carcinoma and enhancing tumor thrombus in the left portal vein who presented with abdominal pain, decreased appetite, and weight loss. Post-treatment axial T1-weighted magnetic resonance imaging post-contrast image demonstrating improved tumor thrombus in the left portal vein (white arrow).
Figure 6:
A 65-year-old male with bilobar hepatocellular carcinoma and enhancing tumor thrombus in the left portal vein who presented with abdominal pain, decreased appetite, and weight loss. Post-treatment axial T1-weighted magnetic resonance imaging post-contrast image demonstrating improved tumor thrombus in the left portal vein (white arrow).

DISCUSSION

The presence of arterioportal shunts in HCC impacts the efficacy and safety of radioembolization due to particles siphoning off through the shunt, potentially leading to underdosing of the target lesion and increased deposition of radiation in normal liver tissue leading to further liver damage. The risk of adverse events after radioembolization is highest with non-segmental and large shunts.[3] Permanent occlusion of some shunts is possible with various embolic agents including polyvinyl alcohol, lipiodol gelatin, sponge granules, cyanoacrylate, and coils and could potentially be followed by typical radioembolization.[5,6] However, these strategies carry additional risks including non-target embolization, portal vein occlusion, or proximal embolization thus preventing access to the tumor for future treatment.[7] To date, there are no clear guidelines in management of large APS due to PVTT.

This case demonstrates a technique that allows delivery of Y-90 beads to the target tumoral tissue in the setting of significant portal vein shunting that would otherwise redistribute the particles throughout the liver, resulting in insufficient dose to the tumor and high does to non-target liver parenchyma. The occlusion balloon in the arterial side of the portal vein shunt decreases the pressure in the arterial system compared to the portal vein, thereby reversing flow away from the shunt. The degree to which this happens is dependent on the intrahepatic collaterals that perfuse the target artery distal to the balloon.

CONCLUSION

Balloon-occlusion-assisted transarterial radiation segmentectomy may be an effective method to increase tumor response and decrease the rate of complications in patients with HCC and arterioportal shunting undergoing radiation segmentectomy. Future prospective studies may be warranted to determine the feasibility and safety of adding balloon-occlusion transarterial radioembolization segmentectomy to standardized treatment algorithms.

Acknowledgments

This case was accepted as a poster at global embolization symposium technologies (GEST) 2023.

Declaration of patient consent

Patient’s consent not required as patient’s identity is not disclosed or compromised.

Conflicts of interest

Dr. Sivananthan is a consultant for Boston Scientific and on the medical advisory board for Embolix inc.

Financial support and sponsorship

We plan to apply for support from embolix to pay any publication/processing fee.

References

  1. , , , , , , et al. Dosimetry based on 99mTc-macroaggregated albumin SPECT/CT accurately predicts tumor response and survival in hepatocellular carcinoma patients treated with 90Y-loaded glass microspheres: Preliminary results. J Nucl Med. 2012;53:255-63.
    [CrossRef] [PubMed] [Google Scholar]
  2. , , , , , , et al. Radiation segmentectomy: A novel approach to increase safety and efficacy of radioembolization. Int J Radiat Oncol Biol Phys. 2011;79:163-71.
    [CrossRef] [PubMed] [Google Scholar]
  3. , , , , , . Safety of radioembolization in the setting of angiographically apparent arterioportal shunting. J Vasc Interv Radiol. 2018;29:1511-8.
    [CrossRef] [PubMed] [Google Scholar]
  4. , , . Excessive hepatic arterial-portal venous shunting may predict failure of microparticle localization in hepatocellular carcinomas. World J Nucl Med. 2013;12:48-50.
    [CrossRef] [PubMed] [Google Scholar]
  5. , , , , , . Hepatic arterioportal fistulas: A retrospective analysis of 97 cases. J Clin Transl Hepatol. 2022;10:620-6.
    [CrossRef] [PubMed] [Google Scholar]
  6. , , , , , , et al. Transarterial embolization with cyanoacrylate for severe arterioportal shunt complicated by hepatocellular carcinoma. Cardiovasc Intervent Radiol. 2013;36:412-21.
    [CrossRef] [PubMed] [Google Scholar]
  7. , , , , , , et al. Endovascular embolization by transcatheter delivery of particles: Past, present, and future. J Funct Biomater. 2017;8:12.
    [CrossRef] [PubMed] [Google Scholar]

Fulltext Views
49,986

PDF downloads
4,117
View/Download PDF
Download Citations
BibTeX
RIS
Show Sections